cagrilintide trial In the REDEFINE 2 phase 3a involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide is an amylin analogue

Pricing Comparison The structural and manufacturing differences translate to pricing: GHK-Cu is one of the more affordable peptides in the catalog due to its simple three-amino-acid structure and well-established manufacturing BPC-157 is mid-range pricing more expensive per mg than GHK-Cu but less expensive than the highly modified metabolic peptides For broader pricing context, see Peptide Pricing in Canada: What Drives Cost and How to Evaluate Value

Expiry and Storage: Never use expired vials

The genetic test predispositions can be interpreted with your qualified healthcare provider to support more informed conversations about whether GLP-1 therapy aligns with your metabolism and lifestyle

2 AdamsM